Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer

Not Applicable

Completed

• Conditions: Colorectal Neoplasms
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: Synbiotics

• Registration Number: NCT01479907
• Lead Sponsor: University of Athens

Brief Summary

The aim of this double-blinded prospective randomised trial is to explore the potential benefits of early postoperative administration of Synbiotics (combination of prebiotics and probiotics) to patients who have undergone colectomy for cancer. The patients are randomised to either synbiotics or placebo administration at the day they are able to tolerate po liquid diet and for 15 days thereafter.

Primary end points of the study will be:

Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively by the use of the validated questionnaire GIQLI (Gastrointestinal Quality of Life Index)

Secondary end points will be:

-Assessment of functional bowel disorders (diarrhea, constipation, etc) at 1, 3 and 6 months postoperatively based on the respective domains of the validated instrument EORTC QLQ-C30

Detailed Description

The study patients are randomized before surgery to receive either synbiotics (Synbiotics group) or placebo (Control group). Equal randomization is accomplished using a computer-generated random allocation schedule. The method of allocation concealment is sequentially numbered sealed opaque envelopes technique. Both synbiotics and placebo preparations are in foil-sealed sachets stored in identical numbered containers. Both study products are white powders, identical in weight, smell, and taste. Thus, the identity of the specific product is blind to participants, support staff and investigators for the entire duration of the study period.

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2011-11-16
• Study First Submitted QC: 2011-11-25
• Study First Posted: 2011-11-28
• Primary Completion: 2012-03
• Study Completion: 2015-09
• Status Verified: 2016-05
• Last Update Submitted: 2016-05-11
• Last Update Posted: 2016-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Colectomy for histologically proven colorectal adenocarcinoma

Exclusion Criteria

• Pregnancy,
• hereditary cancer,
• history of inflammatory bowel disease,
• metastatic disease at presentation,
• emergency operation,
• major postoperative complications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
Synbiotics	Synbiotics	A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, "IONIA" Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 \[11\] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days.

Primary Outcome Measures

Name	Time	Method
Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively	2 years

Trial Locations

Locations (1)

First Department of Propaedeutic Surgery of Athens Medical School, Hippocration General Hospital; 🇬🇷 Athens, Greece